IN2014DN00090A - - Google Patents

Download PDF

Info

Publication number
IN2014DN00090A
IN2014DN00090A IN90DEN2014A IN2014DN00090A IN 2014DN00090 A IN2014DN00090 A IN 2014DN00090A IN 90DEN2014 A IN90DEN2014 A IN 90DEN2014A IN 2014DN00090 A IN2014DN00090 A IN 2014DN00090A
Authority
IN
India
Prior art keywords
pharmaceutical
parkinson
disease
treatment
composition containing
Prior art date
Application number
Inventor
Michael Dey
Joel Richard
Marie Madeleine Baronnet
Nathalie Mondoly
Laurent Bertocchi
Jeremiah Harnett
Original Assignee
Britannia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Britannia Pharmaceuticals Ltd filed Critical Britannia Pharmaceuticals Ltd
Publication of IN2014DN00090A publication Critical patent/IN2014DN00090A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to a pharmaceutical composition containing apomorphine as the active pharmaceutical ingredient co solvent antioxidant water having a pH greater than 4. The pharmaceutical formulation is suitable for parenteral administration for the treatment of Parkinson s disease
IN90DEN2014 2011-07-11 2012-07-11 IN2014DN00090A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11290320A EP2545905A1 (en) 2011-07-11 2011-07-11 A new therapeutical composition containing apomorphine as active ingredient
PCT/EP2012/002916 WO2013007381A1 (en) 2011-07-11 2012-07-11 A new therapeutical composition containing apomorphine as active ingredient

Publications (1)

Publication Number Publication Date
IN2014DN00090A true IN2014DN00090A (en) 2015-05-15

Family

ID=46514305

Family Applications (1)

Application Number Title Priority Date Filing Date
IN90DEN2014 IN2014DN00090A (en) 2011-07-11 2012-07-11

Country Status (29)

Country Link
US (4) US11026938B2 (en)
EP (2) EP2545905A1 (en)
JP (2) JP6356064B2 (en)
KR (1) KR101990897B1 (en)
CN (2) CN103826612B (en)
AU (1) AU2012283381B2 (en)
BR (1) BR112014000306B1 (en)
CA (1) CA2841807C (en)
CL (1) CL2014000050A1 (en)
CO (1) CO6870038A2 (en)
CR (1) CR20140005A (en)
CU (1) CU24159B1 (en)
DO (1) DOP2014000003A (en)
EA (1) EA025870B1 (en)
EC (1) ECSP14013200A (en)
GE (1) GEP20196969B (en)
GT (1) GT201400003A (en)
IL (1) IL230308A (en)
IN (1) IN2014DN00090A (en)
MA (1) MA35411B1 (en)
MX (2) MX2014000454A (en)
MY (1) MY168212A (en)
NI (1) NI201400003A (en)
PE (1) PE20141539A1 (en)
SG (1) SG10201605491PA (en)
TN (1) TN2014000001A1 (en)
UA (1) UA113962C2 (en)
WO (1) WO2013007381A1 (en)
ZA (1) ZA201309711B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2545905A1 (en) * 2011-07-11 2013-01-16 Britannia Pharmaceuticals Limited A new therapeutical composition containing apomorphine as active ingredient
NZ703341A (en) * 2012-06-05 2016-11-25 Neuroderm Ltd Compositions comprising apomorphine and organic acids and uses thereof
EP2918266A1 (en) 2014-03-11 2015-09-16 CDRD Berolina AB Composition comprising a dopamine agonist and an L-DOPA derivative for treating Parkinson's disease
EP2979688A1 (en) * 2014-08-01 2016-02-03 Britannia Pharmaceuticals Limited Composition containing Apomorphine and a Divalent Metal Cation
RU2017123762A (en) * 2014-12-23 2019-01-24 Нейродерм Лтд CRYSTAL FORMS OF APOMORPHINE AND THEIR APPLICATION
EP3355887A1 (en) 2015-09-28 2018-08-08 EVER Neuro Pharma GmbH Aqueous composition of apomorphine for subcutaneous administration
CN114007617A (en) * 2019-05-31 2022-02-01 葡瑞慕生物技术有限公司 Unit dosage form for transmucosal administration of pharmaceutically active ingredients
US20220313682A1 (en) * 2019-08-07 2022-10-06 Aclipse One Inc. Pharmaceutical Compositions of (6aS)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol
US20230181570A1 (en) 2020-05-20 2023-06-15 Medrx Co., Ltd. Transdermal Formulation Containing Apomorphine
WO2022271537A1 (en) * 2021-06-25 2022-12-29 President And Fellows Of Harvard College Compositions and methods relating to injectable microemulsions
WO2023242355A1 (en) 2022-06-15 2023-12-21 Ever Neuro Pharma Gmbh Apomorphine prodrugs and uses thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1662566A1 (en) * 1988-03-05 1991-07-15 Всесоюзный Научно-Исследовательский Институт Биотехнологии Method for stabilization of injectable apomorphine solution
JP2822049B2 (en) * 1989-02-02 1998-11-05 ゼリア新薬工業株式会社 Aqueous formulation composition
EP0865789B1 (en) * 1993-03-26 2005-03-16 Franciscus Wilhelmus Henricus Maria Merkus Pharmaceutical compositions for intranasal administration of dihydroergotamine
US6121276A (en) * 1994-04-22 2000-09-19 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage forms for ameliorating male erectile dysfunction
US5562917A (en) * 1994-12-23 1996-10-08 Pentech Pharmaceuticals, Inc. Transdermal administration of apomorphine
US5945117A (en) 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction
JP3723857B2 (en) * 1998-02-04 2005-12-07 日本ケミカルリサーチ株式会社 Aqueous pharmaceutical composition containing human growth hormone
US6011043A (en) 1998-06-19 2000-01-04 Schering Corporation Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
US6436950B1 (en) * 1998-08-14 2002-08-20 Nastech Pharmaceutical Company, Inc. Nasal delivery of apomorphine
US5994363A (en) * 1998-08-24 1999-11-30 Pentech Pharmaceuticals, Inc. Amelioration of apomorphine adverse effects
BR0005797A (en) * 2000-03-20 2001-10-16 Abbott Lab Methods for the treatment of sexual dysfunction with apomorphine at specified plasma concentration levels
US20020169166A1 (en) 2001-03-09 2002-11-14 Cowart Marlon D. Benzimidazoles that are useful in treating sexual dysfunction
US20030008878A1 (en) 2001-03-09 2003-01-09 Cowart Marlon D. Benzimidazoles that are useful in treating sexual dysfunction
ITMI20011321A1 (en) * 2001-06-22 2002-12-22 Chiesi Farma Spa MICROEMULSION PHARMACEUTICAL COMPOSITION SUITABLE FOR TRANSMINISTRIC ADMINISTRATION OF APOMORPHINE USEFUL IN TREATMENT OF
US20040028613A1 (en) * 2001-06-25 2004-02-12 Nastech Pharmaceutical Company Inc Dopamine agonist formulations for enhanced central nervous system delivery
PE20030762A1 (en) 2001-12-18 2003-09-05 Schering Corp HETEROCYCLIC COMPOUNDS AS NK1 ANTAGONISTS
US6939094B2 (en) 2003-01-28 2005-09-06 Macro Technologies Inc. Autonomous power interface for modifying limited rotation speed of a machine
WO2004089988A2 (en) 2003-04-03 2004-10-21 Protein Design Labs, Inc Inhibitors of integrin alpha5beta1 and their use for the control of tissue granulation
US20050090518A1 (en) * 2003-10-24 2005-04-28 Nastech Pharmaceutical Company Inc. Method for treating parkinson's disease using apomorphine and apomorphine prodrugs
EP1714648A4 (en) * 2004-02-09 2010-05-26 Aska Pharm Co Ltd Combination drug
MX2008014910A (en) 2006-05-24 2009-01-23 Bayer Schering Pharma Ag HIGH AFFINITY HUMAN AND HUMANIZED ANTI-alpha5beta1 INTEGRIN FUNCTION BLOCKING ANTIBODIES WITH REDUCED IMMUNOGENICITY.
US20080171072A1 (en) * 2006-08-11 2008-07-17 Frank Burczynski Ocular inserts containing apomorphine
US8741918B2 (en) * 2007-06-21 2014-06-03 Veroscience Llc Parenteral formulations of dopamine agonists
EP2057982A1 (en) * 2007-11-09 2009-05-13 Archimedes Development Limited Intranasal compositions
CN101712675B (en) * 2008-10-07 2013-07-03 江苏恒谊药业有限公司 Nitrogenous benzheterocycle derivate and application thereof in treating nervous and mental diseases
EP2545905A1 (en) * 2011-07-11 2013-01-16 Britannia Pharmaceuticals Limited A new therapeutical composition containing apomorphine as active ingredient

Also Published As

Publication number Publication date
CR20140005A (en) 2014-07-21
CA2841807C (en) 2018-02-20
CL2014000050A1 (en) 2014-08-18
EA201400067A1 (en) 2015-02-27
WO2013007381A1 (en) 2013-01-17
AU2012283381B2 (en) 2017-07-27
MX2014000454A (en) 2014-09-01
MY168212A (en) 2018-10-15
EP2545905A1 (en) 2013-01-16
BR112014000306B1 (en) 2022-03-29
AU2012283381A1 (en) 2014-02-06
US11026938B2 (en) 2021-06-08
US20210244724A1 (en) 2021-08-12
ZA201309711B (en) 2014-08-27
CA2841807A1 (en) 2013-01-17
GEP20196969B (en) 2019-04-25
TN2014000001A1 (en) 2015-07-01
US11766431B2 (en) 2023-09-26
CU24159B1 (en) 2016-03-31
US20160310480A1 (en) 2016-10-27
US20140128422A1 (en) 2014-05-08
CN103826612A (en) 2014-05-28
CU20140005A7 (en) 2014-04-24
MA35411B1 (en) 2014-09-01
NI201400003A (en) 2015-10-12
ECSP14013200A (en) 2014-04-30
JP2017081947A (en) 2017-05-18
CN108434094A (en) 2018-08-24
BR112014000306A2 (en) 2017-02-07
KR20140072861A (en) 2014-06-13
CO6870038A2 (en) 2014-02-20
EP2731589A1 (en) 2014-05-21
PE20141539A1 (en) 2014-10-25
JP2014518285A (en) 2014-07-28
KR101990897B1 (en) 2019-06-19
DOP2014000003A (en) 2014-06-01
MX2021010046A (en) 2021-09-21
EA025870B1 (en) 2017-02-28
US20180098981A1 (en) 2018-04-12
SG10201605491PA (en) 2016-08-30
UA113962C2 (en) 2017-04-10
JP6356064B2 (en) 2018-07-11
GT201400003A (en) 2017-09-28
IL230308A (en) 2017-04-30
CN103826612B (en) 2020-07-28

Similar Documents

Publication Publication Date Title
IN2014DN00090A (en)
NZ608116A (en) Triazine-oxadiazoles
UA110354C2 (en) Anti-viral compounds
IN2014MN02598A (en)
GEP201706620B (en) NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS
IN2014MN01755A (en)
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
UA109220C2 (en) (4-phenylimidazol-2-yl)ethylamine derivatives as sodium channel modulators
IN2014CN04530A (en)
IN2015DN01119A (en)
IN2012DN02139A (en)
PH12015502802A1 (en) Formulation comprising a hypolipidemic agent
PH12016501977A1 (en) 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES
MX364400B (en) Tetracycline compounds.
IN2012DN02502A (en)
WO2012135615A3 (en) Enopeptins, uses thereof, and methods of synthesis thereto
IN2014DN05972A (en)
MX2013002620A (en) Novel n-hydroxy-benzamides for the treatment of cancer.
EA201490573A1 (en) CONTAINING BENZOTHIAZOLONE
IN2013DN02555A (en)
MX2016004909A (en) Composition containing eugenol as active ingredient for preventing or treating atopic dermatitis.
IN2015DN01329A (en)
MY164880A (en) Process for the preparation of isoxazolyl-methoxy-nicotinic acids
MX2013012773A (en) Drug substances, pharmeceutical compositions and methods for preparing the same.
IN2014MN02433A (en)